Salvage Radiopharmaceutical Therapy (RPT) in Neuroendocrine Carcinoma (NEC) after standard treatment failure: Clinical experience with α-emitters and combinations of FAP-directed and antagonist SSTR-directed approaches (EANM 2026) - Sep 29, 2026 - Abstract #EP-0866; "Previous treatments included chemotherapy (n=6), radiotherapy (n=5), surgery (n=4), somatostatin analogues (n=3), 177Lu-DOTATATE PRRT (n=2), everolimus (n=1)...Four patients underwent FRT: one received 1x90Y-3BP-3940; one 1xTANDEM 225Ac/177Lu-3BP-3940; one 2x177Lu-3BP-3940 and 1x90Y-3BP-3940; one 1x225Ac-3BP-3940 and 3xTANDEM 225Ac/177Lu-3BP-3940... In this small heavily-pretreated cohort of NEC patients, salvage RPT, including approaches based on α-emitters, FAP-targeting and SSTR-agonists/antagonists, was feasible and overall well tolerated. However, treatment efficacy was very limited, supporting further investigation to optimize it, including integration with other therapeutic strategies."
Clinical • Endocrine Cancer • Hematological Disorders • Leukopenia • Neuroendocrine Carcinoma • Oncology • Solid Tumor • Thrombocytopenia • SSTR
|
|
E. Perrone 1, 2; K. Ghai 2; T. Parkar 2; A. Eismant 2; S. Stephan 2; L. Greifenstein 2; M. Pavel 3; R. P. Baum 2
|